Development of In Situ Gelling Liquid Extended Release System for Oral Delivery of Abiraterone Acetate Mohamed M. Shehata, Mona F. Arafa, Ahmed E. Goda, Gamal M. El Maghraby AAPS Pharmscitech, 2026 Abiraterone acetate (ABA) belongs to low permeability low solubility class. It exhibits pH-dependent solubility with slightly better solubility at gastric pH. It may thus undergo supersaturation and precipitation after gastric emptying. ABA may undergo premature hydrolysis in intestinal lumen which decreases the amount absorbed. This can contribute to its low bioavailability. The aim was to formulate ABA in self-emulsifying drug delivery system (SEDDS), which was loaded in in situ gelling system made of alginate or alginate and chitosan. This can provide controlled release of ABA, preventing possible precipitation with SEDDS augmenting absorption. Alginate and alginate-chitosan based formulations were developed based on gelling capacity. SEDDS comprising oleic acid with Tween 80 and glycerol was fabricated and loaded into in situ gelling formulations. The release behavior was monitored using continuous pH variation. The oral bioavailability of ABA was assessed indirectly by monitoring rat total serum testosterone level. Results indicated that both increasing the concentration of alginate and adding chitosan contributed to enhanced gelation. Loading ABA in SEDDS hastened its dissolution. Loading into in situ gelling system resulted in controlled release with alginate-chitosan system showing better retention of ABA in stomach and intestinal phases. The total serum testosterone level was 8.18, 3.43, 1.51, 3.4 and 0.25 ng/ml for control rat, rats receiving ABA aqueous suspension, ABA in SEDDS, ABA SEDDS in 1% alginate and ABA SEDDS in 1% alginate/1% chitosan. The results suggested that SEDDS can prevent premature degradation and controlling the release within the stomach and intestine maximize the efficacy. Graphical Abstract
Menthol-based self microemulsifying drug delivery system for augmented intestinal absorption of edoxaban Ola A Refaey, Gamal M El Maghraby, Mona F Arafa, Heba I Elagamy Journal of Pharmacy and Pharmacology, 2026 Background Clinical effectiveness of edoxaban is hindered by poor solubility and limited permeability due to P-glycoprotein (P-gp) efflux. Aim The aim was to hasten dissolution and intestinal permeability of edoxaban by loading into microemulsion system consisting of menthol as oil and inhibitor of P-gp. Methods Pseudo-ternary phase diagram was constructed at 37°C and microemulsion comprising menthol, tween 80, ethanol and water at ratio of 20:30:30:20 was selected and evaluated. Results Microemulsion’s droplet size was 163.47 nm, its polydispersity index was 0.28, and its zeta potential was −16.43 mV. Edoxaban was loaded in water-free system for dissolution testing. This system underwent self microemulsification in dissolution medium to increase dissolution efficiency to 95.39%, compared with 66.64% for unprocessed edoxaban. Stability assessments demonstrated the system’s stability against various stress conditions. In situ intestinal perfusion studies indicated improved permeability, with 2.96-fold increase in the duodenum and 2.06-fold increase in the ileum compared with edoxaban in aqueous solution. This enhanced absorption was attributed to inhibition of P-gp-mediated efflux by menthol and Tween 80, as well as increased membrane fluidity and permeability. Conclusion These encouraging outcomes highlight the potential of microemulsion in improving both solubility and intestinal permeability of edoxaban enhancing of its oral bioavailability and therapeutic effectiveness.
Tomographic evaluation of apexogenesis with human treated dentin matrix in young permanent molars: a split-mouth randomized controlled clinical trial Nora M. Abo Shanady, Nahed A. Abo Hamila, Gamal M. El Maghraby, Rehab F. Ghouraba BMC Oral Health, 2025 Background The concept of vital pulp therapy (VPT) of immature permanent teeth has evolved in recent years. There has been a great tendency towards investigating new pulp capping materials for perfect imitation for natural dentin-pulp complex formation process and restoring the normal tissue’s characteristics. Therefore, this study aimed to assess the clinical and tomographic outcomes of apexogenesis with human treated dentin matrix (hTDM) compared to mineral trioxide aggregate (MTA). Materials and methods 40 bilateral deep carious young mandibular first permanent molars (FPMs) in 20 healthy children aged between 6 and 8 years old were randomly allocated into 2 groups in which the FPMs treated with hTDM and MTA after pulpotomy procedure. The children were followed up clinically at 3, 6, 12, and 18 months. Tomographic evaluation was performed at baseline and 18-month evaluation period. Results The overall clinical success rate was 100% in both groups. Regarding tomographic evaluation, the mean differences in root length, periapical diameter and area were statistically significant in each individual group but without statistically significant differences between both groups. Conclusion Human TDM hydrogel could be considered a promising pulpotomy agent for immature permanent teeth. Trial registration The current clinical trial was recorded at clinicaltrials.gov, NCT06116695, 27/10/2023, Retrospectively registered.
Preparation and evaluation of rapidly dissolving tablets of raloxifene hydrochloride by ternary system formation International Journal of Pharmacy and Pharmaceutical Sciences, 2016
Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide Pakistan Journal of Pharmaceutical Sciences, 2011
Design of programmable release formulations for combined therapy International Journal of Pharmtech Research, 2011
Dry co-processing of Velpatasvir for Enhancing its Pharmaceutical and Biopharmaceutical Properties SS Mahmoud, GM El Maghraby, AA Donia, TM Yassin, SM Ashmawy Journal of Pharmaceutical Innovation 21 (3), 297 , 2026 2026
Capryol-Ethyl oleate self-microemulsifying system for improved intestinal absorption and hypoglycemic activity of empagliflozin EM Hathout, SS Eltokhy, DH Abdelkader, GME Maghraby Pharmaceutical Development and Technology, 1-21 , 2026 2026
Soft and solid lipid-based nanostructures for dermal and transdermal drug delivery GM El Maghraby, ND Fayed Journal of Drug Delivery Science and Technology, 108459 , 2026 2026
Niosomes in nanofibers for ocular delivery of nimodipine MA Marouf, MF Arafa, ER Kenawy, TB Edries, GM El Maghraby Journal of Drug Delivery Science and Technology 119, 108129 , 2026 2026
Efficacy of Nd: YAG Laser Versus Photodynamic Therapy Using Combination of 5 Aminolevulinic Acid and Intense Pulsed Light in the Treatment of Nail Psoriasis Randomized … SA Eldelee, YMEH Neinaa, GM El Maghraby, WH Mahmoud, ... Journal of the American Academy of Dermatology, S0190-9622 (26) 02570-3 , 2026 2026
Niosome-Based Vaccine Against Experimental Cystic Echinococcosis: Histological and Biochemical Evaluation AM Khattab, SM Elmarhoumy, NMF Hassan, GM El Maghraby, ... Acta Tropica, 108078 , 2026 2026
Development of In Situ Gelling Liquid Extended Release System for Oral Delivery of Abiraterone Acetate MM Shehata, MF Arafa, AE Goda, GM El Maghraby AAPS PharmSciTech 27 (3), 158 , 2026 2026
Menthol-based self microemulsifying drug delivery system for augmented intestinal absorption of edoxaban OA Refaey, GM El Maghraby, MF Arafa, HI Elagamy Journal of Pharmacy and Pharmacology 78 (1), rgaf085 , 2026 2026
Modulation of Bilastine Crystallinity for Enhanced Dissolution and Oral Bioavailability ZM Elrefaey, RK Eid, MF Arafa, M Nasr, GM El Pharmaceutical Sciences, - , 2025 2025
Fabrication and Characterization of Amisulpride Nanofibers for Enhanced Oral Pharmacodynamic Properties SM Ashmawy Journal of Pharmaceutical Sciences , 2025 2025
Enhancement of Lurasidone Hydrochloride Dissolution and Pharmacodynamic Properties Via Co-crystal and Eutectic Formation MA Hussien, SE Abu-Risha, EA Essa, GM El Maghraby, SM Ashmawy Journal of Pharmaceutical Innovation 20 (5), 200 , 2025 2025
Niosomes as a vehicle for excretory/secretory antigens enhance immunization efficacy of Toxoplasma gondii vaccine SS Younis, GA Gamea, GM El Maghraby, MF Arafa, RA Khalifa, ... Experimental Parasitology, 109024 , 2025 2025 Citations: 3
Development of sustained release oral disintegrating tablet of fluvoxamine maleate EA Shetaa, MF Arafa, SE Abu-Risha, GM El Maghraby Pharmaceutical Development and Technology 30 (7), 1036-1046 , 2025 2025
Niosomes for enhanced oral delivery of pioglitazone: in vitro characterization and in vivo evaluation AR Elbasuony, AE Abdelaziz, EA Mazyed, GM El Maghraby Journal of Pharmacy and Pharmacology 77 (8), 1075-1084 , 2025 2025 Citations: 2
Clinical and radiographic evaluation of apexogenesis with human treated dentin matrix in young permanent molars NMA Shanady, NAA Hamila, GM El Maghraby, RF Ghouraba Tanta Dental Journal 22 (3), 549-556 , 2025 2025
Tomographic evaluation of apexogenesis with human treated dentin matrix in young permanent molars: a split-mouth randomized controlled clinical trial NMA Shanady, NA Abo Hamila, GM El Maghraby, RF Ghouraba BMC Oral Health 25 (1), 692 , 2025 2025 Citations: 2
Photodynamic Therapy With Liquid Crystal Loaded Methylene Blue in the Treatment of Verruca GFR Hassan, YSI El‐Amawy, GM El Maghraby, AM Abdel‐Latif Photodermatology, Photoimmunology & Photomedicine 41 (3), e70023 , 2025 2025
Nanoemulsion for enhanced absorption and anti-tumor activity of dasatinib DA Eltahan, RK Eid, SM Ashmawy, GM El Maghraby Journal of Drug Delivery Science and Technology 107, 106870 , 2025 2025 Citations: 4
Controlled anti-solvent precipitation for enhanced dissolution rate and antiplatelet activity of ticagrelor AM Eldeeb, DH Abdelkader, GM El Maghraby Pharmaceutical Development and Technology 30 (4), 463-473 , 2025 2025 Citations: 2
Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of finasteride and silodosin HF Marei, MF Arafa, GM El Maghraby Scientific Reports 15 (1), 8928 , 2025 2025 Citations: 7
MOST CITED SCHOLAR PUBLICATIONS
Liposomes and skin: from drug delivery to model membranes GM El Maghraby, BW Barry, AC Williams European journal of pharmaceutical sciences 34 (4-5), 203-222 , 2008 2008 Citations: 884
Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration GMM El Maghraby, AC Williams, BW Barry International journal of pharmaceutics 196 (1), 63-74 , 2000 2000 Citations: 418
Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants GM El Maghraby International Journal of Pharmaceutics 355 (1-2), 285-292 , 2008 2008 Citations: 334
Can drug‐bearing liposomes penetrate intact skin? GMME Maghraby, AC Williams, BW Barry Journal of Pharmacy and Pharmacology 58 (4), 415-429 , 2006 2006 Citations: 329
Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes GMM El Maghraby, AC Williams, BW Barry International journal of pharmaceutics 276 (1-2), 143-161 , 2004 2004 Citations: 300
Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro GMME Maghraby, AC Williams, BW Barry Journal of Pharmacy and Pharmacology 53 (8), 1069-1077 , 2001 2001 Citations: 276
Skin delivery of oestradiol from deformable and traditiona liposomes: mechanistic studies GMMEL MAGHRABY, AC Williams, BW Barry Journal of Pharmacy and Pharmacology 51 (10), 1123-1134 , 1999 1999 Citations: 275
Skin delivery of oestradiol from lipid vesicles: importance of liposome structure GMM El Maghraby, AC Williams, BW Barry International journal of pharmaceutics 204 (1-2), 159-169 , 2000 2000 Citations: 218
Skin hydration and possible shunt route penetration in controlled estradiol delivery from ultradeformable and standard liposomes GMM El Maghraby, AC Williams, BW Barry Journal of Pharmacy and Pharmacology 53 (10), 1311-1322 , 2001 2001 Citations: 163
Drug interaction and location in liposomes: correlation with polar surface areas GMM El Maghraby, AC Williams, BW Barry International Journal of Pharmaceutics 292 (1-2), 179-185 , 2005 2005 Citations: 141
Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation J Chan, GMM El Maghraby, JP Craig, RG Alany International journal of pharmaceutics 328 (1), 65-71 , 2007 2007 Citations: 140
Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition GM El Maghraby Colloids and Surfaces B: Biointerfaces 75 (2), 595-600 , 2010 2010 Citations: 138
Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide SA El-Gizawy, MA Osman, MF Arafa, GM El Maghraby International journal of pharmaceutics 478 (2), 773-778 , 2015 2015 Citations: 120
Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin GM El Maghraby, AC Williams Expert Opinion on Drug Delivery 6 (2), 149-163 , 2009 2009 Citations: 110
Development and validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma HA Mowafy, FK Alanazi, GM El Maghraby Saudi Pharmaceutical Journal 20 (1), 29-34 , 2012 2012 Citations: 100
Fast disintegrating tablets of nisoldipine for intra-oral administration GM El Maghraby, RN Elsergany Pharmaceutical development and technology 19 (6), 641-650 , 2014 2014 Citations: 96
Optimization of niosomes for enhanced antibacterial activity and reduced bacterial resistance: in vitro and in vivo evaluation AA Abdelaziz, TE Elbanna, FI Sonbol, NM Gamaleldin, GM El Maghraby Expert opinion on drug delivery 12 (2), 163-180 , 2015 2015 Citations: 91
Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis RK Eid, DS Ashour, EA Essa, GM El Maghraby, MF Arafa Carbohydrate polymers 232, 115826 , 2020 2020 Citations: 83
Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir IA Alsarra, AY Hamed, GM Mahrous, GM El Maghraby, AA Al-Robayan, ... Drug development and industrial pharmacy 35 (3), 352-362 , 2009 2009 Citations: 82
Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes GMM El Maghraby, M Campbell, BC Finnin International Journal of Pharmaceutics 305 (1-2), 90-104 , 2005 2005 Citations: 82